Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blinded, Vehicle-Controlled, Multicenter, Parallel-Group Study of APL-9 in Mild to Moderate Acute Respiratory Distress Syndrome Due to COVID-19

NCT04402060 is registered in ClinicalTrials.gov with Apellis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04402060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04402060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blinded, Vehicle-Controlled, Multicenter, Parallel-Group Study of APL-9 in Mild to Moderate Acute Respiratory Distress Syndrome Due to COVID-19
Lead sponsor
Apellis Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
May 28, 2020
Completion date
February 13, 2021
Enrollment
72 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome, ards, coronavirus, coronavirus infection, covid, covid-19, sars-cov2, severe acute respiratory syndrome, severe acute respiratory syndrome coronavirus 2